Background: The aim of this study is to evaluate long term clinical outcomes of drugeluting stent (DES) and bare metal stent(BMS) with large vessel diameter and single coronary lesions for 5 years. Methods: A total of 428 consecutive patients who visited 3 medical centers from March 2003 to April 2007 and had a single coronary lesion which was treated with the use of a DES or BMS that was more than 3.5 mm in diameter were enrolled in this study. Patients were divided into 2 stent groups: DES (n¼299), BMS (n ¼ 129). The study end point was a composite of major adverse cardiac events (MACE) including death, myocardial infarction (MI), and target-vessel revascularization (TVR) for five years Results: Baseline characteristics were not different. 5 years follow up rate was 82.5% (355/428). The cumulative MACE rate for 5 years were not different between two group ( 20.4% in BMS vs. 18% in DES, p¼0.592). The rate of MI (3.1% in BMS vs. 2.4% in DES, p¼0.513), death (3.7% in BMS vs. 2.0% in DES, p¼0.361) and TVR (12% in BMS vs. 10.6% in DES, p¼0.694) were not different. There was no difference in MACE-free survival rate between the DES group and the BMS group (93.1% in DES vs 90.7% in BMS, P¼0.472). Conclusions: Clinical outcomes between DES and BMS are similar in a large vessel diameter and single coronary arterial lesion for 5 years.
Background: The aim of this study is to evaluate long term clinical outcomes of drugeluting stent (DES) and bare metal stent(BMS) with large vessel diameter and single coronary lesions for 5 years. Methods: A total of 428 consecutive patients who visited 3 medical centers from March 2003 to April 2007 and had a single coronary lesion which was treated with the use of a DES or BMS that was more than 3.5 mm in diameter were enrolled in this study. Patients were divided into 2 stent groups: DES (n¼299), BMS (n ¼ 129). The study end point was a composite of major adverse cardiac events (MACE) including death, myocardial infarction (MI), and target-vessel revascularization (TVR) for five years Results: Baseline characteristics were not different. 5 years follow up rate was 82.5% (355/428 HCor, São Paulo, Brazil Background: Saphenous vein graft (SVG) percutaneous coronary intervention (PCI) carries unique technical challenges due to the soft and friable nature of the SVG lesions, increasing the risk of adverse events associated with distal embolization. Our objective was to evaluate the efficacy of the MGuard TM stent to prevent early adverse events. Methods: The present analysis enrolled consecutive patients with SVG lesions percutaneoulsy treated at two Institutions with distinct strategies. At the public institution, all patients were treated with the dedicated MGuard stent while at the private hospital SVG PCI was performed with regular DES. Distal protection filters were available at both hospitals and their use was left at operator's discretion. The primary objective included the occurrence of in-hospital major adverse cardiovascular events (MACE), composite of death, non-fatal myocardial infarction and target lesion revascularization (TLR). Results: A total of 271 patients were evaluated, 51 in the MGuardTM group and 220 patients in the DES group. Most of baseline characteristics were statistically similar in both groups, however MGuard patients had more renal insufficiency (25.9% vs. 12.5%; P ¼ 0.001), and previous myocardial infarction (58.8% vs. 35.9%; P ¼ 0.003). There were less in-hospital major adverse cardiovascular events in the MGuardTM cohort (1.96% vs. 13.6%; P ¼ 0.014, OR 7.89, CI 1.05-59.3), exclusively due to the difference in periprocedural myocardial infarction (1.96% vs. 13.6%; P ¼ 0.014), with none inhospital death or TLR in both groups. Conversely, at 1 year clinical follow up, MACE rate was significantly higher among patients treated with MGuard (14.28% vs. 4.4%; P ¼ 0.01, OR 0.24, CI 0.07-0.76), with no statistically difference in cardiac death (2.38% vs. 2.56%; P ¼ 0.94) or myocardial infarction (4.76% vs. 0.64%; P ¼ 0.09), but markedly more TLR in the MGuardTM group (7.14% vs. 1.28%; P ¼ 0.048). Conclusions: The dedicated MGuard stent have been effective in reducing periprocedural MI, although the higher occurrence of one-year target-lesion restenosis offset this initial benefit when compared to drug-eluting stents. 
